XNAS · Healthcare · Biotechnology
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.79 | -0.83 | -5.06% | $0 | ❌ Miss | -0.45% | +10.40% | — |
| 2026-03-03 | Q4 2025 | -0.87 | -0.88 | -1.15% | $0 | ❌ Miss | -3.06% | +1.06% | +12.86% |
| 2025-11-14 |
| Q3 2025 |
| -0.85 |
| -0.90 |
| -5.88% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.66 | -0.98 | -48.48% | $0 | ❌ Miss | +0.35% | -7.61% | -9.26% |
| 2025-02-27 | Q4 2024 | -0.63 | -0.61 | +3.17% | $0 | ✅ Beat | +7.95% | +0.47% | -10.60% |
| 2024-11-12 | Q3 2024 | -0.60 | -0.66 | -10.00% | $0 | ❌ Miss | +2.70% | +4.50% | +56.23% |
| 2024-05-07 | Q1 2024 | -0.48 | -0.59 | -22.92% | $0 | ❌ Miss | -1.29% | -4.63% | -35.81% |
| 2024-03-19 | Q4 2023 | -0.49 | -0.50 | -2.04% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.